Maker of implantable neuromodulation devices for epilepsy and heart-lung support systems used in cardiac surgery.
Maker of implantable neuromodulation devices for epilepsy and heart-lung support systems used in cardiac surgery.
Implanted vagus-nerve stimulators earn on the initial surgery and again on battery replacement, so the base of patients is a recurring source of sales. Heart-lung machines are sold to hospitals along with the disposable parts used in every operation. The company is working to extend its stimulator to depression, which would widen its market.
Moat: narrow (regulatory licence, switching costs, installed base). FDA-approved implantable neuromodulation platform with long device-replacement cycles and surgeon training lock-in.
Headquarters: London, United Kingdom · Founded: 2015 · Employees: 3,300
Size LivaNova (LIVN) is a United States Health Care company (Medical Specialties) with a market value of $5.21B, the 1149th largest of 3,085 United States companies the cockpit tracks. Shares closed at $94.54 on 18 Nov 2026.
Performance Over six months the shares gained 28.3%, against +24.2% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 11.7% over the last twelve months (peer median +3.5%); the operating margin is 15.1% (peer median 15.1%).
Valuation It trades at 20.9× forward earnings against a peer median of 20.0× (8th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.1 points above its cost of capital (9.4% WACC).
Credit LivaNova has 1 bond outstanding ($345M).
Short interest Short interest is 11.6% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.51B | $1.39B | $1.25B | $1.15B | $1.02B |
| Revenue growth | — | +11% | +9% | +13% | — |
| Gross profit | $1.03B | $944M | $872M | $785M | $718M |
| EBITDA | $294M | $285M | $217M | $160M | $180M |
| Net income | $196M | -$242M | $63.2M | $17.5M | -$86.2M |
| Free cash flow | $129M | $173M | $136M | $39.9M | $43.4M |
| Capital expenditure | $109M | $81.0M | $47.1M | $35.0M | $26.5M |
| Total debt | $357M | $434M | $677M | $640M | $580M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| LivaNova LIVN | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| Terumo 4543.T | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% |
| Getinge GETI-B.ST | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LIVN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.6% | +8.6% | 3rd highest of 21 |
| 6-month return | +28.3% | +24.2% | 9th highest of 21 |
| Distance from 52-week high | -4.9% | -10.3% | 6th highest of 21 |
| Revenue growth (TTM) | +11.7% | +3.5% | 8th highest of 21 |
| Operating margin | 15.1% | 15.1% | 11th highest of 21 |
| Forward P/E | 20.9× | 20.0× | 8th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 14.2% | 11.8% | 7th most demanding of 17 |
| Growth delivered (Del g) | +8.2% | +9.1% | 8th lowest of 17 |
| Hurdle (Req g minus delivered) | +5.9 pp | +1.8 pp | 6th most demanding of 17 |
| ROIC minus cost of capital | +6.1 pp | +2.5 pp | 6th highest of 21 |
| EV / EBITDA | 17.0× | 14.8× | 7th most expensive of 15 |
| Net debt / EBITDA | -0.7× | 1.1× | 3rd least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |
| Merit Medical Systems MMSI | United States | $5.15B | +33% | +9% | 14% | 19.1× | 12.6% | +9.5% |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| Intco Medical Technology 300677.SZ | China | $4.82B | -2% | +33% | 20% | 18.5× | -3.5% | -6.4% |
| DiaSorin DIA.MI | Italy | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% | +6.3% |
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |
| Sotera Health SHC | United States | $4.65B | +5% | +7% | 37% | 15.7× | 14.4% | +7.3% |
| GRAIL GRAL | United States | $4.59B | +67% | +17% | -332% | n/a | n/a | n/a |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| Lantheus LNTH | United States | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% | +35.3% |
| Cochlear COH.AX | Australia | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% | +9.3% |
| ConvaTec CTEC.L | United Kingdom | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% | +4.6% |
| Ypsomed YPSN.SW | Switzerland | $6.83B | +27% | -13% | 30% | 31.7× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
LivaNova has 1 bond outstanding with $345M face value.